한빛사 논문
경희대학교 의과대학
Wansun Kim a,1, Soogeun Kim a,1, Jisang Han b,1, Tae Gi Kim c, Ayoung Bang a, Hyung Woo Choi d, Gyeong Eun Min e, Jae-Ho Shin c,***, Sang Woong Moon c,**, Samjin Choi a,*
a Department of Biomedical Engineering, College of Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea b Department of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, 06351, Republic of Korea c Department of Ophthalmology, College of Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea d Department of Mechanical Engineering, Sogang University, Seoul, 04107, Republic of Korea e Department of Urology, College of Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea
* Corresponding author.
** Corresponding author.
*** Corresponding author.
1 These authors contributed equally to this work.
Abstract
We introduce a label-free surface-enhanced Raman scattering (SERS) biosensing platform equipped with metallic nanostructures that can identify the efficacy of Oxford-AstraZeneca (AZD1222) vaccine in vaccinated individuals using non-invasive tear samples. We confirmed the hypothesis that the tears of people who receive the AZD1222 vaccine may be similar to those of adenovirus epidemic keratoconjunctivitis patients since the Oxford-AstraZeneca vaccine is derived from a replication-deficient ChAdOx1 vector of chimpanzee adenovirus. Additionally, we confirmed the potential of the three markers for estimating the vaccination status via analyzing the signals emanating from antibodies or immunoglobulin G by-product using our label-free, SERS biosensing technique with a high reproducibility (<3% relative standard deviation), femtomole-scale limit of detection (1 × 10−14 M), and high SERS response of >108. Therefore, our label-free SERS biosensing nanoplatforms with long-term storage and robust stability will enable rapid and robust monitoring of the vaccine presence in vaccinated individuals.
논문정보
관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기